RedHill Biopharma Ltd. RDHL
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 143.00K | 286.00K | 3.02M | 5.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 143.00K | 286.00K | 3.02M | 5.76M |
| Cost of Revenue | -- | -- | -- | -- | 894.00K |
| Gross Profit | -- | 143.00K | 286.00K | 286.00K | 2.13M |
| SG&A Expenses | 2.51M | 2.61M | 2.72M | -4.64M | -1.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.48M | 3.58M | 3.68M | -5.50M | -866.00K |
| Operating Income | -3.48M | -3.43M | -3.39M | 483.00K | -1.42M |
| Income Before Tax | -5.72M | -4.33M | -2.94M | 3.10M | 513.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.72 | -4.33 | -2.94 | 3.10 | 0.51 |
| Earnings from Discontinued Operations | -381.00K | -789.50K | -1.20M | -1.20M | -1.20M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.10M | -5.12M | -4.13M | -6.72M | -9.31M |
| EBIT | -3.48M | -3.43M | -3.39M | 483.00K | -1.42M |
| EBITDA | -3.34M | -3.28M | -3.23M | 491.00K | -1.57M |
| EPS Basic | -34.38K | -45.84K | -45.84K | -54.69K | -63.76K |
| Normalized Basic EPS | -- | -0.51 | -1.02 | 1.48 | 0.81 |
| EPS Diluted | -34.38K | -45.84K | -45.84K | -54.69K | -63.76K |
| Normalized Diluted EPS | -- | -0.51 | -1.02 | 1.48 | 0.81 |
| Average Basic Shares Outstanding | 3.16M | 4.96M | 6.77M | 4.84M | 6.05M |
| Average Diluted Shares Outstanding | 1.00K | 800.00 | 600.00 | 400.00 | 400.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |